Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Amon-Re Iguana sun care line silicone technology provides "immediate" sun protection.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

AMON-RE IGUANA SUN CARE LINE PROMOTED AS "IMMEDIATE" PROTECTION, with active sunscreen ingredients delivered via a patent-pending silicone emulsifier system that provides "full SPF and waterproof protection on contact," according to the Thomasville, Ga.-based R&D firm. The firm's branded entry into the sun care market uses a silicone technology that works in a manner similar to the volatile silicone technology found in transfer-resistant makeup, Amon-Re explained. The emulsion system, however, gives the product more "breathability" and flexibility with skin than is often found in transfer-resistant cosmetics, the company added. Shipping to drug stores and supermarkets nationwide, the 14-SKU line includes Sport and Kids products, as well as a number of self-tanners.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

See All
UsernamePublicRestriction

Register

PS088170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By